Table 3. Results From the Conditional Logistic Regression Analyses Within Treatment Group for the Additive Genetic Effect of the Minor Allele of rs1967309.
| Treatment | Genotype | Patients With Events | Patients Without Events | OR (95% CI) | |
|---|---|---|---|---|---|
| Unadjusted | Adjusteda | ||||
| 5-Component MACE | |||||
| Evacetrapib | AA | 125 | 130 | 0.99 (0.89-1.10) | 1.02 (0.91-1.14) |
| AG | 349 | 379 | |||
| GG | 245 | 254 | |||
| Placebo | AA | 143 | 129 | 1.15 (1.03-1.27) | 1.06 (0.95-1.19) |
| AG | 353 | 378 | |||
| GG | 212 | 262 | |||
| 3-Component MACE | |||||
| Evacetrapib | AA | 74 | 181 | 1.03 (0.90-1.20) | 1.02 (0.88-1.18) |
| AG | 191 | 537 | |||
| GG | 131 | 368 | |||
| Placebo | AA | 81 | 191 | 1.01 (0.88-1.17) | 0.87 (0.75-1.00) |
| AG | 191 | 540 | |||
| GG | 143 | 331 | |||
Abbreviations: MACE, major adverse cardiovascular events; OR, odd ratio.
a
Adjusted for sex, top 5 principal components, and risk factors, including baseline apolipoprotein B, history of cerebral vascular disease, history of peripheral arterial disease, history of prior percutaneous coronary intervention, history of prior myocardial infarction, region, race/ethnicity, and smoking status in an interaction model with treatment and SNP main effects and treatment-by-SNP interaction effect.